NEW YORK – Adaptive Biotechnologies this week announced the closing of its initial public offering of 15 million shares of common stock and the exercise in full of the underwriters' option to purchase 2.25 million additional shares at a public offering price of $20 per share. Gross proceeds from the offering were approximately $345 million before deducting underwriting discounts and commissions and estimated offering expenses. Adaptive's shares began trading on Nasdaq on June 27 under the ticker symbol "ADPT."
Thermo Fisher Scientific said on June 28 that it has completed the sale of its Anatomical Pathology business to global healthcare company PHC Holdings for approximately $1.14 billion in cash. The deal was originally announced in January. The Anatomical Pathology business has approximately 1,200 employees in the US, Europe, and Asia and generated approximately $350 million in annual revenue. It was part of Thermo Fisher's Specialty Diagnostics business segment.
TATAA Biocenter said this week that it will distribute MethylDetect's DNA methylation assays in Scandinavia and the Czech and Slovak Republics. MethylDetect's assays are based on methylation-sensitive high-resolution melting technology and offer high specificity and sensitivity, TATAA said. The assays will also be used in TATAA's accredited molecular analysis services and training courses, the center said.
New England Biolabs has opened an Australia subsidiary, the company's eighth subsidiary worldwide. The new subsidiary in Melbourne will provide the scientific research community in Australia and New Zealand with more efficient access to NEB products and technical support, as well as OEM partnership opportunities, Andrew Boslem, general manager for the Australia office, said in a statement. NEB, headquartered in Ipswich, Massachusetts, also maintains subsidiaries in Canada, China, France, Germany, Japan, Singapore, and the UK.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.